BioAge Labs, Inc. (BIOA)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-05) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-08) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-24) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-06) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-06) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-06) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-20) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-07) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | — |
|
| Unaudited Condensed Consolidated Balance Sheets | — |
|
| Consolidated Balance Sheets (P) | — |
|
| Unaudited Condensed Consolidated Balance Sheets (P) | — |
|
| Consolidated Statements of Operations and Comprehensive Loss | — |
|
| Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss | — |
|
| Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity | — |
|
| Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (deficit) | — |
|
| Unaudited Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (deficit) | — |
|
| Unaudited Condensed Consolidated Statements of Stockholders' Equity | — |
|
| Condensed Consolidated Statements of Cash Flows | — |
|
| Unaudited Condensed Consolidated Statements of Cash Flows | — |
|
| Notes | ||
| Balance Sheet Components | ||
| Basis of Presentation | ||
| Basis of Presentation and Significant Accounting Policies | ||
| Capital Structure | ||
| Collaboration Agreements | ||
| Commitments and Contingencies | ||
| Cybersecurity Risk Management, Strategy, and Governance | — |
|
| Debt | ||
| Employee Benefit Plan | ||
| Fair Value Measurements | ||
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Net Loss Per Share Attributable To Common Stockholders | ||
| Pay Vs Performance Disclosure | ||
| Segment Reporting | ||
| Stock-based Compensation | ||
| Subsequent Events | ||
| Wellcome Leap Commercial Research Funding Agreement | — |
|